Akero Therapeutics Inc (NASDAQ: AKRO) is 94.39% higher on its value in year-to-date trading and has touched a low of $15.32 and a high of $58.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKRO stock was last observed hovering at around $55.36 in the last trading session, with the day’s loss setting it -1.28%.
Currently trading at $54.08, the stock is 67.14% and 74.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing -2.31% at the moment leaves the stock 102.17% off its SMA200. AKRO registered 142.08% gain for a year compared to 6-month gain of 102.32%. The firm has a 50-day simple moving average (SMA 50) of $31.0025 and a 200-day simple moving average (SMA200) of $26.749874.
The stock witnessed a 93.42% loss in the last 1 month and extending the period to 3 months gives it a 70.44%, and is 106.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.08% over the week and 6.90% over the month.
Akero Therapeutics Inc (AKRO) has around 56 employees, a market worth around $4.06B and $0.00M in sales. Distance from 52-week low is 253.00% and -7.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.65%).
The EPS is expected to shrink by -37.37% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Akero Therapeutics Inc (AKRO) Top Institutional Holders
250.0 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 103.07% of the company’s shares. The shares outstanding are 69.61M, and float is at 62.71M with Short Float at 5.34%. Institutions hold 97.79% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 6.88 million shares valued at $161.28 million. The investor’s holdings represent 11.5942% of the AKRO Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.59 million shares valued at $131.06 million to account for 9.4197 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.43 million shares representing 9.159% and valued at over $127.43 million, while GENERAL ATLANTIC, L.P. holds 8.8251 of the shares totaling 5.23 million with a market value of $122.79 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Yale Catriona, the company’s Chief Development Officer. SEC filings show that Yale Catriona sold 53,590 shares of the company’s common stock on Jan 27 ’25 at a price of $56.25 per share for a total of $3.01 million. Following the sale, the insider now owns 95648.0 shares.
Akero Therapeutics Inc disclosed in a document filed with the SEC on Jan 27 ’25 that Yale Catriona (Chief Development Officer) sold a total of 49,074 shares of the company’s common stock. The trade occurred on Jan 27 ’25 and was made at $55.72 per share for $2.73 million. Following the transaction, the insider now directly holds 95648.0 shares of the AKRO stock.
Still, SEC filings show that on Jan 27 ’25, Rolph Timothy (Chief Scientific Officer) disposed off 31,250 shares at an average price of $55.77 for $1.74 million. The insider now directly holds 170,237 shares of Akero Therapeutics Inc (AKRO).
